Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers
Not Applicable
Completed
- Conditions
- Healthy
- Registration Number
- NCT00958399
- Lead Sponsor
- University of Minnesota
- Brief Summary
Research suggests dietary fiber may play a role in weight management, and fiber consumption is inversely associated with body weight, body fat, and BMI in cross-sectional studies. These effects may be mediated by increased satiety, reduced food intake, or changes in blood levels of glucose, insulin, and gut hormones.
The purpose of this study is to determine the satiety, glycemic, hormonal, and gastrointestinal responses of novel fiber supplements.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- healthy men and women
- age 18-60 years
- non-smoking
- not taking medication
- non-dieting (weight stable in prior 3 months)
- BMI 18-27
- English literacy
- ability to give blood
Exclusion Criteria
- do not regularly consume breakfast
- food allergies to ingredients found in study products
- dislike for muffins, fiber bars, or hot cereal
- BMI <18 or >27
- diagnosed cardiovascular, renal, or hepatic disease
- diabetes mellitus (fasting blood sugar >126 mg/dl)
- cancer in previous 5 years (except basal cell carcinoma of the skin)
- any gastrointestinal disease or condition
- recent bacterial infection (< 3 months)
- recent or concurrent participation in an intervention research study
- history of drug or alcohol abuse in prior 6 months
- use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication
- restrained eaters
- vegetarians
- people who eat more than approximately 15 grams of fiber per day
- women who are pregnant or lactating
- women with irregular menstrual cycles
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Satiety 0, 15, 30, 45, 60, 90, 120, 180, 215 minutes postprandially
- Secondary Outcome Measures
Name Time Method ad libitum food intake 180 minutes postprandially and over 24 hours Ghrelin, polypeptide YY (PYY), and glucagon-like peptide-1 (GLP-1) response 0, 30, 60 minutes postprandially Gastrointestinal tolerance and fecal chemistry following 7 days of treatment Glucose/Insulin Response 0, 15, 30, 45, 60, 90, 120, 180 minutes postprandially
Trial Locations
- Locations (1)
University of Minnesota - General Clinical Research Center
🇺🇸Minneapolis, Minnesota, United States
University of Minnesota - General Clinical Research Center🇺🇸Minneapolis, Minnesota, United States